Vivek Subbiah, MD

Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know - OncoDaily Vivek Subbiah: We Don’t Just Write What We Know, We Write to Discover What We Could Know / cancer, Nature Reviews Bioengineering, OncoDaily, Oncology, Vivek

What is Missing to Fully Harness Precision Medicine and Transform Cancer Care - Vivek Subbiah
@viveksubbiah.bsky.social
@natmed.nature.com

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PrecisionMedicine

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification - OncoDaily Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Happy 4th everyone! Delighted to share with the our comment just published in t...

It’s Time We Evolve WHO Cancer Classification - Vivek Subbiah
@viveksubbiah.bsky.social
@who.int

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerClassification #WHO

Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options - OncoDaily Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options / cancer, OncoDaily, Oncology, Sarah Cannon Research Institute, Sarcoma

How Clinical Trials Offer Hope for Those Facing Limited Options - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/clinica...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrial #Sarcoma #SarcomaAwarenessMonth

Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥
www.annalsofoncology.org/article/S092...

Vivek Subbiah: Cancer Isn’t Just a Human Disease - It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - OncoDaily Vivek Subbiah: Cancer Isn’t Just a Human Disease - It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs / Amy M. Boddy,

Cancer Isn’t Just a Human Disease – It’s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Medicine #Health

25 Posts Not to Miss from EHA 2025: - OncoDaily The European Hematology Association (EHA 2025) congress is officially underway in Milan. From June 12 to 15, hematology professionals from

25 Posts Not to Miss from EHA 2025
@nicogagelmann.bsky.social @talhabadarmd.bsky.social @majorajay.bsky.social @vincentrk.bsky.social @viveksubbiah.bsky.social @nejm.org

oncodaily.com/societies/eh...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #EHA25

Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? - OncoDaily Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? / Bettina Ryll, Branko Cuglievan, cancer, clinical trials, FDA, Howard A. Burris

Why Every Rare Cancer Patient Deserves Molecular Profiling? - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/insight/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RareCancers #MolecularProfiling

Super interesting.

"Tissue-agnostic #cancer therapies promise 2 revolutionize oncology by targeting molecular drivers. [A] study of nearly 300K tumors found 21.5% w/tissue-agnostic indications. Despite 9 #FDA approvals, real-world implementation challenges ..." 1/2 #CanSky #OncSky #ASCO25

Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.’s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...

⭐️Tissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines ASCO and Google Cloud's AI tool is meant to help oncologists query just its trusted cancer treatment guidelines, without extraneous information.

ASCO and Google create ‘walled garden’ AI tool for doctors to query group’s guidelines www.statnews.com/2025/05/21/a... via @statnews.com

Vivek Subbiah: Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer - OncoDaily Vivek Subbiah: Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer / ASCO25, cancer, fight against cancer, Global fight

Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/team-of...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrialsDay #ASCO25

Inspiring Journey of the 2024 Yvonne Awardees — A Year of Impact and Leadership - OncoDaily Inspiring Journey of the 2024 Yvonne Awardees — A Year of Impact and Leadership / Africa oncology, Asia cancer research, CAN-PIVOT project, cancer, cancer

Inspiring Journey of the 2024 Yvonne Awardees - A Year of Impact and Leadership
@drasyaagulnik.bsky.social
@viveksubbiah.bsky.social

oncodaily.com/blog/yvonne-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Yvonne #Leadership

⭐️To all the incredible moms who fill our lives with love, strength, and wisdom-today is for you.
🙏🏽Thank you for being the heart of every home & the foundation of so many dreams. Happy Mother’s Day! 💐❤️ #MothersDay

Vivek Subbiah: Exhilarating discussions on new podcast - Immunoverse - OncoDaily Vivek Subbiah: Exhilarating discussions on new podcast - Immunoverse / Aung Naing, cancer, fight against cancer, Global fight against cancer, ImmunoVerse,

Exhilarating discussions on new podcast: Immunoverse - Vivek Subbiah

@viveksubbiah.bsky.social @patrickhwumd.bsky.social @moffittnews.bsky.social

oncodaily.com/blog/immunov...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunoverse #Podcast

Excited to be part of this #AACR25 (@theaacr.bsky.social @rickbuck.bsky.social) Social Media Ambassadorship!!

Look out for updates on the #Tumor-microenvironment ( #TME )-relevant events and highlights. I’ll be posting from Sunday afternoon to midday Wednesday 😎

@theaacr.bsky.social, @hkbeasley.bsky.social, @drkatiec.bsky.social, @katiekickscancer.bsky.social, @tme-caf-ecm.bsky.social, @manelesteller.bsky.social, @cancerassassin1.bsky.social, @anirbanmaitra.bsky.social, @coloncancergal.bsky.social, @anguspratt.bsky.social, @arosen380.bsky.social

🚨The #AACR25 buzz is building! I’m thrilled to be a Social Media Ambassador for this year’s #AACR Annual Meeting.
👉🏼Please join me & all the ambassadors as we spotlight the exciting science. Research matters—and so does sharing it. Join the convo with @theaacr.bsky.social @rickbuck.bsky.social

Excited and honored to be a Social Media Ambassador for @theaacr.bsky.social #AACR25 Follow along with me here and on LinkedIn to experience the Annual Meeting with me starting this Friday in Chicago. Kicking off with #AACRAMC Grant Writing Workshop Friday afternoon! #AACRECR
go.bsky.app/Jj6Efme

Abstracts are out for #ASCO25!
5000+ studies. 5 Plenary game-changers.
@ascocancer.bsky.social @oncoalert.bsky.social @drchoueiri.bsky.social @ptarantinomd.bsky.social @viveksubbiah.bsky.social @oncbrothers.bsky.social

We're so excited about #AACR25 that we just created a starter pack for all their Social Media Ambassadors on #MedSky - almost all are here! Follow these leaders here for all the AACR lowdown: go.bsky.app/Jj6Efme

Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches | JCO Oncology Advances There have been significant advances in colorectal cancer (CRC) immunotherapy over the past decade, with incorporation into both the metastatic and adjuvant/neoadjuvant treatment spaces. However, ther...

Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy

Awesome! Congratulations 🎉

Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur ...

🚨🚨🚨Pleased to share our article in @ascocancer.bsky.social Ed book
👉🏼Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras 🦓🦓🦓 ascopubs.org/doi/10.1200/...

🚨 Hot off the press! 🚨 The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology 🧬🏥
www.annalsofoncology.org/article/S092...

Graphic promoting a Plenary Session at Great Debates in Solid Tumors. Session name: Tumor Agnostic Therapies - Revolutionizing Cancer Treatment: From Tissue-Specific to Target-Driven. Speaker is Vivek Subbiah, MD, Chief, Early Phase Drug Development, Sarah Cannon Research Institute. How are tumor-agnostic therapies shaping your practice? Let us know below! Bottom of the graphic showcases the logos for all three tracks at GD Solid Tumors - Women's, Gastrointestinal, and Lung Cancers

📢 Agenda Spotlight: Plenary Session

Are tumor-agnostic therapies the future of cancer treatment? Dr. @viveksubbiah.bsky.social will explore this evolving shift at **Great Debates in Solid Tumors**.

Join the conversation: www.hmpglobalevents.com/gdst

#GDST25 #MedicalEducation #GreatDebates #Cancer

Promotional graphic for Great Debates in Solid Tumors, highlighting its partnership with Sarah Cannon Research Institute (SCRI) and featuring four speakers. The image has a blue background with a stylized New York City skyline, including the One World Trade Center. At the top, the event's logo and SCRI branding appear. The text reads, 'Join us in New York City, March 22–23, 2025.' Below, four headshots of speakers are displayed with their names and titles: Erika Hamilton, MD (Director, Breast Cancer Research Program), Kathleen Moore, MD, MS (Associate Director of Clinical Research), Vivek Subbiah, MD (Chief, Early Phase Drug Development), and Andrew McKenzie, MD (Vice President, Personalized Medicine). The design includes a mix of white, yellow, and orange text over the blue background.

Proud to collaborate with @scrinetwork.bsky.social at Great Debates in Solid Tumors!

Join Co-Chairs @erikahamilton9.bsky.social & @drkatymoore.bsky.social, plus Andrew McKenzie PhD, & @viveksubbiah.bsky.social, leading key discussions on solid tumors.

🔗 gdsolidtumors.com

#Oncology #CancerResearch

🚨 Precision Dosing IS Precision Oncology 🧬💡

An editorial in Annals of Oncology by Dr. @viveksubbiah.bsky.social reframes precision oncology, arguing that “precision dosing is precision oncology.” 👇

#Onco404 #Oncology #Cancer #PrecisionOncology #CancerResearch #PersonalizedMedicine

📢 It has been a learning experience over the past 3 days at #ESMOTAT25 to listen to experts in the field of #phaseI #drugdevelopment

🗣️ The talks were truly insightful
✅ New and improved drugs 🎯
📊 Innovative trial designs

@myesmo.bsky.social
@viveksubbiah.bsky.social
@oncoalert.bsky.social

Management of Adverse Events Associated with FGFR Inhibitors

Check out Dr. @viveksubbiah.bsky.social's insights on managing #FGFR inhibitor side effects. Proactive monitoring is key to better outcomes in #urothelialcarcinoma and #cholangiocarcinoma: bit.ly/4129EXD

Dr. Subbiah is also faculty at #GDST → www.hmpglobalevents.com/gdst

#MedicalEducation #Cancer